Synapse - Works

Results (116513)

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Meeting Abstract

Abida, W.; Campbell, D.; Patnaik, A.; Sautois, B.; Shapiro, J.; Vogelzang, N. J.; Bryce, A. H.; McDermott, R.; Ricci, F.; Rowe, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients

Meeting Abstract

Italiano, A.; Nanda, S.; Keating, K.; Childs, B. H.; Fellous, M.; Drilon, A.; Hyman, D. M.
Annals of Oncology (2019)

Fulltext@MSK | Save

POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Meeting Abstract

Hammel, P.; Kindler, H. L.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Borgman-Hagey, A. E.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Meeting Abstract

Drilon, A.; Rogers, E.; Zhai, D.; Deng, W.; Zhang, X.; Lee, D.; Ung, J.; Whitten, J.; Zhang, H.; Liu, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Meeting Abstract

Hyman, D. M.; Tan, D. S. W.; van Tilburg, C. M.; Albert, C. M.; Geoerger, B.; Farago, A. F.; Laetsch, T. W.; Kummar, S.; Doz, F.; Lassen, U. N.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Meeting Abstract

Govindan, R.; Fakih, M. G.; Price, T. J.; Falchook, G. S.; Desai, J.; Kuo, J. C.; Strickler, J. H.; Krauss, J. C.; Li, B. T.; Denlinger, C. S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data

Meeting Abstract

Decaens, T.; Ryoo, B. Y.; Falchook, G. S.; Veillon, R.; Doi, T.; Yamazaki, K.; Hong, D.; Qin, S.; Scheele, J.; Bruns, R.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Achour, I.; Hu, H.; Lewis, L.; Walcott, F. L.; Oosting, S. F.
Annals of Oncology (2019)

Fulltext@MSK | Save

Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt)

Meeting Abstract

Rousseau, B. J. C.; Cohen, J.; Calderaro, J.; Dupuy, A.; Bourgoin, R.; Tournigand, C.; Baumgaertner, I.; Ropert, S.; Thirot Bidault, A.; Klotz, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save